About bsbh

This author has not yet filled in any details.
So far bsbh has created 233 blog entries.

H.R. 3’s international reference pricing misses the mark

By Susan Peschin and Duane Schulthess, April 28, 2021

The White House and Congress have declared that reining in Medicare prescription drug costs to help older adults and people with disabilities is a top priority. But one drug pricing strategy on the table would have an outsized negative impact on people with Alzheimer’s disease and decimate research trying to find effective treatments for it. This strategy, known as international reference pricing, ties the price that Medicare pays for some drugs to those paid by other countries. The idea was first introduced as a model for Medicare Part B drugs by then-HHS Secretary Alex Azar in 2018. The next year, House Speaker Nancy Pelosi’s drug pricing plan, known as the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3), significantly expanded the scope to allow federal government use of foreign price controls in direct negotiations with pharmaceutical companies for the cost of 250 prescription medicines in Medicare Part B and Part D. It also extended the negotiated price to insurers and the commercial market at large.

H.R. 3’s international reference pricing misses the mark2021-04-30T12:39:20+00:00

Webinar: Taking the next step: health literacy and the fight against cancer

14 April, 8.30-9.00 CET

Higher degrees of health literacy support patients at every stage of their journeys: they help to navigate decision-making and elevate patients to partners. If combined with health literate institutions, the coproduction of health can improve patient care and help reduce costs of unnecessary and inappropriate medical intervention.
Policy changes to increase health literacy have been notoriously difficult to implement, due also to a lack of evidence about the correlation between measures to increase health literacy and actual outcomes. Several initiatives have taken on the task to create such evidence. Most recently, Europe’s Beating Cancer Plan promises to make cancer literacy a priority for European policy makers, guidelines, and programs of action.
What do we know about the value of health literacy, where do we need to know more? How can we achieve higher degrees of health literacy? What lessons can we draw from the current pandemic? Join two outstanding experts for an Early Bird discussion on health literacy!

REGISTER

Webinar: Taking the next step: health literacy and the fight against cancer2021-04-14T11:27:17+00:00

Belgium makes a U-turn on AstraZeneca jab in over-55s

Belgium is the latest European country to make a U-turn on the AstraZeneca vaccine, now recommending it for use in people over 55 years of age.   The country's Superior Health Council said data from new, large-scale studies in the UK, which showed strong efficacy in older age groups "is reassuring at first sight," and deemed the jab safe and effective.   Belgium was one of a handful of countries – including Germany, France and Italy – that limited the use of the AstraZeneca vaccine last month, despite the European Medicines Agency saying it was safe for anyone over the age of 18. 

Belgium makes a U-turn on AstraZeneca jab in over-55s2021-04-23T08:29:31+00:00

Webinar: Cancer care during a pandemic – what have we learned so far?

10 March, 18:00-18:30

It will probably take years before we can understand the impact of the Covid-19 pandemic on cancer patients. We know about decreasing diagnosis, interrupted treatment cycles, and other unintended effects of pandemic control measures. We don’t know, however, what exactly these changes mean for cancer patients and their survival rates. Even though high-quality data is often lacking and there is significant heterogeneity in real world evidence connecting treatment delays with increased mortality, studies increasingly highlight delays in cancer treatment during the past months. More recently, there have also been attempts to standardize estimates of the effects of treatment delays on survival rates, offering important lessons for cancer care systems. How can we quantify the impact of delays in cancer treatment on mortality? What do we know about the causal links between pandemic control measures and cancer care? How can patients, health care professionals, and policymakers help minimize delays in cancer treatment initiation?

Watch Video
Webinar: Cancer care during a pandemic – what have we learned so far?2021-03-11T10:39:23+00:00

Europe’s Beating Cancer Plan: Why we need it now

10 Feb, 2021, 08:30 – 09:00 CET

"Europe’s Beating Cancer Plan” sounds like something that should be around already. With the Europeans carrying 25% of the global population’s cancer burden, a coherent strategy tackling cancer incidence and mortality in Europe is only consequential. Or is it? Cancer treatment remains a personal and often local matter, and different perspectives exist across Europe on access to cancer care, budgets, and spending. These are reflected in different public health systems and policies at the level of EU member states. Cancer control activities vary greatly within Europe as do the outcomes of cancer care. Considering high European ambitions, persisting interests in member states, and local sensitivities: What can we expect from Europe’s Beating Cancer Plan? How can it become a success and more than just yet another document?

Watch Video
Europe’s Beating Cancer Plan: Why we need it now2021-03-01T09:34:39+00:00

How Europe fell behind on vaccines

The European Union's vaccination effort came under fire just as it was beginning to deliver. Heralded for months as the flagship of European solidarity during the coronavirus pandemic, the European Commission’s strategy of joint vaccine procurement is now being accused by national leaders of being too bureaucratic, too limiting to its members, too slow.

How Europe fell behind on vaccines2021-02-03T08:34:55+00:00

EHDEN Roadshow October 2020 – Public Report

IMI EHDEN presents their online roadshow : a series of 3 webinars focussed on ‘The Role of Health Data in the Post Covid-19 Era’ EHDEN Roadshow October 2020 Public report Download Report Executive Summary The European Health Data [...]

EHDEN Roadshow October 2020 – Public Report2020-12-09T15:06:11+00:00

Cancer prevention: what’s worth the effort?

24 November, 2020, 8.30 CET

As roughly 40% of all cancers are considered preventable, prevention is high on the political agenda. Vaccination programs, environmental policies and supporting healthy lifestyles feature prominently all over the world, including within Europe’s Beating Cancer Plan. When prevention works, it is a cost-effective element of any long-term cancer control strategy. Little is known, however, about the actual effects and causal links between preventive policies on cancer incidence, and mortality. Evidence linking prevention to verified results is scarce, and often unclear regarding which policies and programs work, and to what degree. How strong is the case for cancer prevention? How should prevention be incorporated into national cancer plans? And ultimately, what is the role of prevention in evidenced-based health policy decision-making?

Watch video
Cancer prevention: what’s worth the effort?2021-02-04T11:01:28+00:00

Centralizing Cancer Care? – Quality, costs, and the future of hospitals in Europe

14 October, 2020, 8.30 CET

Centralizing cancer care has been a hot topic for quite some time. Many argue that hospitals are often too small and treat too few patients. Only by pooling resources and specialists in comprehensive cancer centers could high-quality care and equal access to innovative therapies be guaranteed. Yet, the Covid pandemic has shown that reducing the number of hospital beds may also be problematic for the quality of care. Broad availability of hospitals can help intercept epidemic outbreaks and maintain medical expertise – also in oncology. How should the future of inpatient cancer care look like in Europe? Is centralization still the way forward, or do we need to maintain broad operational readiness and expertise?.

Watch video
Centralizing Cancer Care? – Quality, costs, and the future of hospitals in Europe2021-02-04T11:01:37+00:00

Webinar: COVID-19 VACCINES ARE COMING – A Magic Bullet or a Load of Blanks?

Wednesday, 30 September, 20.00 – 21.00 CET (2.00 pm – 3.00 pm, US Eastern)

Given the huge societal and economic impacts of the coronavirus in Europe, everyone is hopeful that COVID-19 vaccines will soon be available – but what happens next? According to an Economist report from August 2018, in the past decade vaccination rates in some European countries have often fallen below those in parts of Africa. It claims that Italy, France and Serbia have lower child-vaccination rates than Burundi, Rwanda and Senegal. After billions of Euros have been invested by governments, what will happen if many EU citizens are unwilling to take the vaccine? What can be done now to ensure that those who need the COVID-19 vaccine most are treated first when the vaccines are available? Furthermore, how do EU member states plan on measuring and monitoring the safety of vaccines that have been rapidly put onto the market ̶ and who will ultimately be accountable? And from the patient’s perspective, how can we build trust around the EU’s management of COVID-19, which has become increasingly politicised?

Watch video
Webinar: COVID-19 VACCINES ARE COMING – A Magic Bullet or a Load of Blanks?2021-02-04T11:01:48+00:00
Go to Top